cover of episode WeightWatchers CEO Sima Sistani talks TikTok, Telehealth Deal on GLP-1/Ozempic and Why She Took the Job

WeightWatchers CEO Sima Sistani talks TikTok, Telehealth Deal on GLP-1/Ozempic and Why She Took the Job

2023/4/6
logo of podcast On with Kara Swisher

On with Kara Swisher

Chapters

Weight Watchers announces a $132 million deal to acquire Sequence, a telehealth company that prescribes GLP-1 drugs, raising questions about the company's shift from personal accountability to medical intervention.

Shownotes Transcript

WeightWatchers recently announced a $132 million deal to acquire telehealth company Sequence and enter the prescription drug space (think: GLP-1 drugs like Wegovy and Ozempic). It begs the question: why is a company built on personal accountability facilitating medical interventions? We ask our guest, WeightWatchers CEO Sima Sistani. Before and after the interview, Nayeema and Kara discuss their own experiences with diet fads and whether drugs like Wegovy and Ozempic will help America deal with the obesity epidemic or simply avoid tackling underlying issues like food supply, corporate greed and light regulation.

Questions? Comments? Email us at [email protected] or find us on Twitter @karaswisher and @nayeema 

Learn more about your ad choices. Visit podcastchoices.com/adchoices)